Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lixte Biotechnology Holdings ( (LIXT) ) just unveiled an update.
On July 9, 2025, Lixte Biotechnology Holdings announced that the journal Nature published findings validating their clinical trials for ovarian and colorectal cancers using their compound LB100. The study, led by Dr. Amir Jazaeri, highlighted that mutations in PPP2R1A, targeted by LB100, improve survival outcomes in ovarian cancer patients. Lixte is conducting trials in collaboration with GSK and Roche to test LB100’s efficacy in combination with immunotherapies, potentially offering new treatment paradigms for cancer patients.
More about Lixte Biotechnology Holdings
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies. The company is pioneering efforts in cancer biology with its lead compound, LB-100, a PP2A inhibitor, which has shown potential to enhance chemotherapies and immunotherapies.
Average Trading Volume: 2,070,583
Technical Sentiment Signal: Hold
Current Market Cap: $7.96M
Find detailed analytics on LIXT stock on TipRanks’ Stock Analysis page.